In the 1950s Yalow and Berson developed a radioimmunoassay for insulin. It was the first case of immunoassay used for diagnostics, measuring glucose levels in diabetic patients. Later, Rosalyn Yalow received a Nobel Prize for this effort. In the 1970s Van Weeman and Schuurs replaced the radiolabel with enzyme labels. This reduced the hazard from radiation, and the turnover of substrate by the enzyme resulted in an amplification of the signal. With radioimmunoassay (RIA) a single binding event was detected by a single radioactive molecule, whereas a single binding event by an enzyme-labeled ligand resulted in increasing color formation as the enzyme turns over substrate. This conversion to enzyme labels also allowed more laboratories to utilize the method since the use of radiolabels often excluded laboratories because of regulatory barriers. Enzyme-linked immunosorbent assays (ELISAs) were also reported to have faster reaction times, greater specificity for the target molecule, and longer shelf lives compared to RIAs.
Accompanying improvements to labels, efforts continue to improve the primary component of the immunoassay, the antibody. Polyclonal antibodies derived from immunizing mammals, primarily rabbits, sheep, goats, and donkey, are a standard reagent. However, the quality of the antibody may not be consistent because of animal to animal variability. In the 1980s, Köhler and Milstein developed a technique that fused antibody-producing B cells to a myeloma cell line. After fusion, an immortal monoclonal cell line producing a single antibody of interest is discovered though screening and results in a cell line that can continuously produce a well-defined reagent. This opened additional doors to commercialization of immunoassays. Recombinant technology has led to the development of antibody molecules expressed in E. coli and the discovery that fragments of the whole antibody molecule retain binding characteristics. Camelid antibodies have been found that have a different morphology consisting of a similar constant region, but the binding portion consists of only the variable heavy chain. This binding portion is 1/10th the size of the classical antibody while retaining high binding affinity and additional properties of thermal and chaotropic stability. Their small size makes them easier to clone and express and modify Despite the long history of immunoassay analysis, research continues today proposing new uses, unique labels, faster homogeneous formats, novel binding reagents, and multiplexing approaches. The versatility of immunoassays is illustrated by the contributions to this special collection of papers. It is clear that they excel as surveillance methods. For example, several papers describe immunoassays that are intended to protect human health by ensuring that food is not contaminated with chemicals, naturally occurring toxins, pathogens, or allergen residues. Another use is for assessing the quality and integrity of the composition of foods, specialty chemicals, and natural products used or consumed by humans. Immunoassay continues to be an important method in disease diagnostics for both humans and food crops. Especially important is the move to pointof-use detection, including using automatic techniques such as lateral flow devices (LFDs). LFDs require little or no laboratory expertise. Rapid and timely detection of toxic chemicals will minimize environmental problems and reduce human exposure. Similarly early detection of pathogens in food crops will result in minimizing pesticide use and decrease crop losses, while bedside detection of infectious diseases will result in more rapid diagnosis and treatment delivered in a more personalized manner leading to decreased mortality and morbidity.
We anticipate that immunoassay technology will continue to play a large role in the protection of human, animal, and environmental health. Adaptation of the technology to field-portable, point-of-use devices will improve health and safety in both developed and more resource-poor developing countries.
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